Monday, 17 December 2012

Acasti’s Capre® Lowers Triglycerides 25% - An All-Natural Blockbuster In The Making?

Acasti Pharma
Shares Outstanding: 71.0 million
Fully Diluted: 80.1 million

Acasti Pharma announced interim results from its phase II open label. Based on an initial sample of 23 patients, of whom 19 had baseline triglyceride levels of between 204 and 476 mg/dl, the data for an eight week treatment with a 2 gram dose showed “a statistically significant” 25% reduction in triglycerides after an eight week treatment period. 

Also, there was a “an important” decrease in  Low Density Lipoprotein (LDL), Very Low Density Lipoprotein (VLDL) and non-HDL lipids and increased High Density Lipoprotein (HDL). This information aligns with the company’s objective of producing “The perfect lipid trifecta”.

Here is a table (data provided by Acasti), which outlines how Acasti’s data stacks up to other cholestrol drugs. 

Dr. Harlan Waksal, Executive Vice-President, Business and Scientific Affairs was quoted in the news release,

"We are pleased with the progress of our clinical efforts. Most notably, we are very satisfied with the significant impact on triglycerides, even in this hard to treat population of patients in the lower strata of hypertriglyceridemia. Achieving statistical significance with such a low number of patients and only after a short eight-week treatment period definitely encourages us to push our strategy forward towards US clinical studies and validation during the upcoming year".       
In response to this morning’s news release Hugh Cleland, Fund Manager at BluMont Capital, said the following:

“This is excellent data. In addition to showing the best trig reduction BY FAR in patients with high triglycerides relative to the 3 competing fish oil drugs, it showed decreases in LDL, AND increases in HDL, something none of GSK, Amarin nor Omthera showed with their drugs in patients with high triglycerides.  It appears we not only have the "best-in-class" fish oil drug, we have something special”.  

“I believe we now have even more visibility on CaPre being a drug that should sell more than $1billion/year (like GSK’s Lovaza), and could very well become a serious blockbuster (multiple billions/year)”.   

To view today’s news release, please click here.